Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Valeant Pharmaceuticals Intl Inc (VRX) and Allergan, Inc. (AGN)’s Hostile Saga Nears Its End

On 18th December the winner of the epic corporate battle between  Allergan, Inc. (NYSE:AGN) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX) which is supported by Pershing Square’s Bill Ackman, will be decided. CNBC‘s David Faber reported that a decisive shareholders’ meeting will be held on the above date.

Valeant Pharmaceuticals Intl Inc (NYSE:VRX)

For those who have not been following one of the most protracted and fierce corporate battles between the two health care companies, Allergan, Inc. (NYSE:AGN) and Valeant Pharmaceuticals Intl Inc (NYSE:VRX), only need to know that Bill Ackman is not a man to be messed with on Wall Street. He won’t stop fighting until he gets what he wants.

On the date mentioned above, Ackman through the company that he is backing, namely Valeant Pharmaceuticals Intl Inc (NYSE:VRX) will try to change the board composition of Allergan, Inc. (NYSE:AGN). He has put up a proposal of 6 directors that in his opinion should replace six of the nine existing directors of Allergan, Inc. (NYSE:AGN).

With this move he plans to pass the vote for  acquisition of the company by Valeant Pharmaceuticals Intl Inc (VRX).

There are two key dates for Valeant Pharmaceuticals Intl Inc (VRX) before the 51 majority shareholders meet on 18th December, according to Faber. One is 20th October, when Valeant’s earnings report comes out and the other is 30th October when it has its own shareholder meeting. A weak earnings report will drive Ackman even further from his acquisition goals, but that is still no indication that he will stop.

Faber said that Allergan still has a few alternatives left to stop this hostile takeover. However, none of them look very promising at this time. Firstly, Valeant could embark on an acquisition mission of its own, thereby depleting the balance sheet capacity of the company that Ackman is using to finance his deal. The second one is to find a white knight, or in other words another company that would acquire Allergen while leaving its management structure intact.

Warren Buffett and BillionairesFree Report: Warren Buffett and 12 Billionaires Are Crazy About These 7 Stocks

Let Warren Buffett, David Einhorn, George Soros, and David Tepper WORK FOR YOU. If you want to beat the low cost index funds by an average of 6 percentage points per year look no further than Warren Buffett’s stock picks. That’s the margin Buffett’s stock picks outperformed the market since 2008. In this free report, Insider Monkey’s market beating research team identified 7 stocks Warren Buffett and 12 other billionaires are crazy about. CLICK HERE NOW for all the details.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.